蔗糖铁治疗血液透析患者肾性贫血的疗效研究  

The Effect Study of Iron Sucrose for Renal Anemia of Chronic Hemodialysis Patients

作　　者：高志光[1] 李彦生[1] 

机构地区：[1]佛山市第二人民医院,广东佛山528000

出　　处：《中外医学研究》2014年第21期40-41,共2页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:研究蔗糖铁在治疗血液透析患者肾性贫血中的应用价值。方法:本组抽取2013年1月-2014年1月笔者所在医院收治的出现肾性贫血的血液透析患者60例,将患者随机分均分为两组,其中观察组患者取蔗糖铁静脉滴注,对照组取多糖铁复合物胶囊口服,两组均联合应用红细胞生成刺激剂(ESA)治疗,治疗12周后观察两组患者的血红蛋白(Hb)、红细胞比积(HCT)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)的变化情况。结果:治疗前,两组患者的Hb、HCT、SF、TSAT比较差异无统计学意义(P>0.05),治疗后观察组患者的上升趋势与对照组比较差异有统计学意义(P<0.05)。观察组不良反应明显低于对照组,差异有统计学意义(P<0.05)。结论:血液透析患者出现肾性贫血时,使用蔗糖铁静脉注射治疗,能够更好纠正患者缺铁,增加铁储备,提高治疗肾性贫血的疗效,值得推广应用。Objective：To study the application value of iron sucrose for renal anemia in chronic hemodialysis patients.Method：60 cases of renal anemia of hemodialysis patients from January 2013 to January 2014 in our hospital were selected,the patients were randomly divided into two groups,the observation group was given intravenous Iron Sucrose,the control group was taken Iron Polysaccharide Complex Capsules,and the two groups were combined use of Erythropoiesis Stimulants（ESA） treatment.After 12 weeks treatment,the change of hemoglobin（Hb）,Hematocrit（HCT）,serum ferritin（SF）,transferrin saturation（TSAT） were observed.Result：Before drug treatment,there were no significant difference between the observation group and the control group in Hb,HCT,SF and TSAT, but after treatment the rising trend of these indicators of the two groups had significant difference（P〈0.05）.The adverse reaction of observation group was significantly lower than that in the control group,there was significant differences（P〈0.05）.Conclusion：Intravenous Iron Sucrose in the treatment of hemodialysis patients with renal anemia can better rectify the iron-deficiency,increase the iron reserves,improve the curative effect of renal anemia,is worthy of popularization and application.

关 键 词：血液透析 肾性贫血 蔗糖铁 

分 类 号：R692.5[医药卫生—泌尿科学]